trending Market Intelligence /marketintelligence/en/news-insights/trending/i7mFQ3a3yjFOyRqs8z00pA2 content esgSubNav
In This List

Mast, Savara secure approval to list on Nasdaq

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Mast, Savara secure approval to list on Nasdaq

Mast Therapeutics Inc. and Savara Inc. said their proposed merged entity received approval to list on the Nasdaq Capital Market under ticker SVRA.

The companies first announced the proposed merger in January.

Though the merger has already been unanimously approved by the boards of both companies, it also needs to be approved by Mast shareholders at an upcoming April 21 special meeting.

Trading of the new company on the Nasdaq is expected to start on the first business day after completion of the merger. Until then Mast will continue to trade on the NYSE MKT.